# OnCo record nct01843374 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct01843374/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct01843374", "NCT01843374" ;
  schema:name "Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma"@en ;
  schema:description "A phase 2 trial of Tremelimumab in mesothelioma, run by MedImmune LLC, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct01843374/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01843374> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2013-05-17" ;
  onco:cancers <https://onco.cc/cancers/mesothelioma/>, <https://onco.cc/cancers/peritoneal-mesothelioma/>, <https://onco.cc/cancers/pleural-mesothelioma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/tremelimumab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .